FDA approves TPOXX ( tecovirimat )
July 13, 2018, The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon.
“To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional option should smallpox ever be used as a bioweapon,” said FDA Commissioner Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermeasure priority review voucher. Today’s action reflects the FDA’s commitment to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.”
July 13, 2018, Prior to its eradication in 1980, variola virus, the virus that causes smallpox, was mainly spread by direct contact between people. Symptoms typically began 10 to 14 days after infection and included fever, exhaustion, headache and backache. A rash initially consisting of small, pink bumps progressed to pus-filled sores before finally crusting over and scarring. Complications of smallpox could include encephalitis (inflammation of the brain), corneal ulcerations (an open sore on the clear, front surface of the eye) and blindness.
TPOXX’s effectiveness against smallpox was established by studies conducted in animals infected with viruses that are closely related to the virus that causes smallpox and was based on measuring survival at the end of the studies. More animals treated with TPOXX lived compared to the animals treated with placebo. TPOXX was approved under the FDA’s Animal Rule, which allows efficacy findings from adequate and well-controlled animal studies to support an FDA approval when it is not feasible or ethical to conduct efficacy trials in humans.
The safety of TPOXX was evaluated in 359 healthy human volunteers without a smallpox infection. The most frequently reported side effects were a headache, nausea and abdominal pain.
The FDA granted this application Fast Track and Priority Review designations. TPOXX also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases and a Material Threat Medical Countermeasure Priority Review Voucher, which provides additional incentives for certain medical products intended to treat or prevent harm from specific chemical, biological, radiological and nuclear threats.
|Chemical Names:||Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R;|
|Molecular Weight:||376.335 g/mol|
DRUG TRIALS SNAPSHOT SUMMARY:
What is the drug for?
TPOXX is a drug for the treatment of smallpox disease.
Smallpox is a serious and highly contagious viral disease that causes fever, rash and deep skin scars and may progress to death. No cases of naturally occurring smallpox disease have happened since the late 1970s because worldwide vaccination led to the eradication of smallpox.
How is this drug used?
TPOXX is taken twice daily for 14 days. The number of capsules per day depends on patient’s weight.
What are the benefits of this drug?
More animals treated with TPOXX lived compared to the animals treated with placebo. Because smallpox disease has been eradicated from the world and it is not feasible or ethical to conduct efficacy trials in humans, the efficacy of TPOXX could not be studied in patients.
Were there any differences in how well the drug worked in clinical trials among sex, race and age?
The efficacy of TPOXX has been studied only in animals, so the differences among patients grouped by sex, race, and age could not be assessed.
The FDA granted approval of TPOXX to SIGA Technologies Inc.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone SwissEmail: email@example.com
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: